

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Melanoma	Melanoma-associated antigen C1 (MAGEC1; CT7)	A study in patient samples and in cell culture suggests that CT7 could boost the activity of immunotherapies for treating melanoma. Patient samples and healthy donors were used to generate CT7-specific T cells <i>in vitro</i> . In cell culture, the CT7-specific T cells showed greater cytotoxicity against human melanoma cells when CT7-activating peptides were added to the medium than when control peptides were added. Next steps include attempting to clone CT7-specific antibodies from patients and evaluating their use as therapeutics and diagnostic reagents for developing cancer immunotherapies.	Patent status undisclosed; CT Atlantic AG has first option to license	Nuber, N. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Aug. 9, 2010; doi:10.1073/pnas.1002155107 <b>Contact:</b> Maries van den Broek, University Hospital Zurich, Zurich, Switzerland e-mail: <a href="mailto:maries@van-den-broek.ch">maries@van-den-broek.ch</a>
		<b>SciBX 3(33); doi:10.1038/scibx.2010.1011</b> Published online Aug. 26, 2010		